Human Microbiome Health
Exploring New Frontiers in Human Microbiome Health
Scientific research is increasingly understanding the unique impact complex and diverse glycans have on immunity and metabolic health.
With this emerging understanding, Gnubiotics has begun applying its innovative glycan technologies to design products which modulate the microbiome safely and effectively by selectively promoting the growth of essential commensal microbes, controlling pathogenic microbes and enhancing the production of metabolites essential for immune protection and regulating inflammatory responses.
Gnubiotics has begun its preclinical research with the goal of enhancing the efficacy of anti-cancer drugs such as ICI’s and act as an anti-inflammatory agent when treating chronic inflammatory diseases such as IBD.
Although immunotherapies have revolutionized the treatment of some cancers, response rates remain suboptimal and differ between patients.
Our candidates aim to capture the therapeutic utility of directly manipulating the microbiome as an approach to control tumoral growth and enhance the efficacy of cancer immunotherapies such as PD-1/PD-L1 inhibitors. Our candidates promote a high microbiome diversity, now recognized as an essential asset in treatment response, and exploit the link between gut microbiota and immune physiology to affect tumor growth and treatment outcome.
Our candidates are currently being tested with the University of Zürich (Switzerland) in mice models of CRC and melanoma tumors.
CRE, ESBL, VRE and MDR P. aeruginosa are all recognized as urgent and serious antibiotic resistance threats by the US Centers for Disease Control (CDC).
Through their ability to fortify the microbiome and selectively promote commensal bacteria over pathogens, our candidates aim to reduce colonization by these pathogenic bacteria and support the maintenance of the intestinal barrier, limiting subsequent systemic infection.
Our candidates are currently being tested in collaboration with NIAID to demonstrate safety and efficacy.
Products & Pipeline CandidatesOur Pipeline:
ℹ AMR infection
CRE, ESBL, VRE, MDR P. aeruginosa
ℹ Inflammatory & Metabolic
Scientific publications & References
Our product candidates are supported by scientific publications involving members of the Gnubiotics team and by third-party evidence.